Hormones
Kisspeptin-10 Protocols for Low Libido in Men and Women
Published August 13, 2026 · 4 minutes
Sexual dysfunction is a primary complaint in functional medicine clinics. Many patients seek alternatives to testosterone replacement therapy or want to avoid the side effects of medications like PT-141. Kisspeptin-10 offers a regulatory approach. It targets the hypothalamic-pituitary-gonadal axis to stimulate the natural release of gonadotropin-releasing hormone. This post outlines how providers can integrate Kisspeptin into their patient protocols.
The Mechanism of Kisspeptin-10
Kisspeptin is a protein encoded by the KISS1 gene. It acts as a gatekeeper for reproductive health. By stimulating GnRH neurons, it triggers the release of luteinizing hormone and follicle-stimulating hormone. Unlike synthetic hormones, it encourages the body to produce its own regulatory signals. This makes it a preferred option for patients concerned about maintaining fertility or natural hormonal balance.
- Stimulates GnRH release in the hypothalamus
- Increases LH and FSH pulses
- Modulates brain activity related to sexual arousal
- Regulates the timing of puberty and reproductive cycles
- Supports natural testosterone production without testicular atrophy
Patient Selection and Indicators
Clinics often prescribe Kisspeptin-10 for patients who do not respond to traditional PDE5 inhibitors or those experiencing psychological libido drops. It is particularly useful for patients with secondary hypogonadism. Before starting, providers should establish baseline blood panels including total testosterone, free testosterone, LH, FSH, and estradiol.
- Patients with low libido despite normal testosterone levels
- Individuals experiencing burnout-related sexual dysfunction
- Patients wanting to avoid the flushing or nausea of PT-141
- Men looking to maintain fertility while improving drive
- Women experiencing low arousal during perimenopause
Standard Clinical Dosing Protocols
Dosing varies based on the specific patient goal. Acute dosing is common for immediate arousal support, while chronic dosing addresses systemic hormonal regulation. Most practitioners start with a low subcutaneous dose and adjust based on patient feedback and follow-up lab work.
- Acute dosing: 100mcg to 200mcg subcutaneous injection
- Maintenance dosing: 100mcg three times per week
- Protocol duration: typically 8 to 12 weeks
- Injection site: abdominal fat or outer thigh
- Monitor for improvements in mood and sexual responsiveness
Comparing Kisspeptin to PT-141
PT-141 acts on melanocortin receptors in the brain to trigger arousal. While effective, it frequently causes nausea and high blood pressure. Kisspeptin-10 works further upstream in the hormonal chain. It generally carries a lower side effect profile and provides a more subtle, physiological response rather than an immediate, pharmacological one.
Integrating Kisspeptin into Your Clinic
Adding Kisspeptin to your menu requires a reliable supply chain. Quality and purity are critical for clinical outcomes. Many med spas bundle Kisspeptin with other wellness therapies like BPC-157 or NAD+ to create comprehensive vitality programs. To view current wholesale options for your practice, apply for a Direct Peptide Sales account.
FAQs
- Does Kisspeptin-10 cause the same side effects as TRT?
- No. Kisspeptin-10 stimulates the natural production of hormones rather than replacing them. It does not typically cause testicular shrinkage or shut down the HPG axis.
- Can women use Kisspeptin-10?
- Yes. Research indicates Kisspeptin plays a vital role in female reproductive health and can be used to address low libido in women, provided hormonal cycles are monitored.
- How quickly do patients see results?
- Some patients report increased arousal within hours of an acute dose. For systemic hormonal improvements, most providers note a timeline of 2 to 4 weeks.
Launch your white-label program
Apply to Direct Peptide Sales, most practices onboard inside 30 days.
Apply now →